Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways

Fig. 2

Syndecan-1 silencing reduces the CD44(+)CD24(-/low) subpopulation and ALDH-1 activity in IBC SUM-149 and non-IBC SKBR-3 cells. a Left panel: A representative flow cytometric analysis of the stem cell-associated cell surface markers CD44 and CD24 in control and Syndecan-1-silenced SUM-149 cells. b and c Representative flow cytometric analysis of ALDH-1-positive SUM-149 and SKBR-3 cells, upon Syndecan-1 knockdown, respectively. Data shown are a single experiment representative of three independent experiments. Right panels of A-C show the quantification of CSC markers as analyzed by flow cytometry. Data represent mean ± SEM, n ≥ 3. ** P < 0.01, * P < 0.05 as determined by Student’s t-test

Back to article page

Molecular Cancer

ISSN: 1476-4598